SEARCH

SEARCH BY CITATION

References

  • 1
    Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). HEPATOLOGY 2000; 32: 477481.
  • 2
    Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003; 38: 14491457.
  • 3
    Bedossa P, Poynard T, Naveau S, Martin ED, Agostini H, Chaput JC. Observer variation in assessment of liver biopsies of alcoholic patients. Alcohol Clin Exp Res 1988; 12: 173178.
  • 4
    Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991; 100: 13971402.
  • 5
    Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci 1994; 39: 24262432.
  • 6
    Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 10691075.
  • 7
    Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert Bismut F, et al. Meta-analyses of Fibrotest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40.
  • 8
    Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3: 167174.
  • 9
    Thabut D, Naveau S, Charlotte F, Massard J, Ratziu V, Imbert-Bismut F, et al. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J Hepatol 2006; 44: 11751185.
  • 10
    Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 18671873.
  • 11
    Anty R, Vanbiervliet G, Gelsi E, Rosenthal A, Huet PM, Saint-Paul MC, et al. Evaluation externe des scores sanguins de fibrose hépatique (Fibrométre, Hepascore, Apri) au cours des hépatopathies alcooliques. Gastroenterol Clin Biol 2006; 30: 1057.
  • 12
    Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. HEPATOLOGY 2005; 42: 13731381.
  • 13
    Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 18871896.
  • 14
    Ngo Y, Benhamou Y, Thibault V, Ingiliz P, Munteanu M, Lebray P, et al. An accurate definition of the status of inactive HBV carrier by a combination of biomarkers (FibroTesT-ActiTest) and viral load. PloS One 2008; 3: e2573.
  • 15
    Poynard T, Naveau S, Doffoel M, Boudjema K, Vanlemmens C, Mantion G, et al. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group. J Hepatol 1999; 30: 11301137.
  • 16
    Naveau S, Perlemuter G, Chaillet M, Raynard B, Balian A, Beuzen F, et al. Serum leptin in patients with alcoholic liver disease. Alcohol Clin Exp Res 2006; 30: 14221428.
  • 17
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. HEPATOLOGY 1996; 24: 289293.
  • 18
    Michalak S, Rousselet MC, Bedossa P, Pilette C, Chappard D, Oberti F, et al. Respective roles of porto-septal fibrosis and centrilobular fibrosis in alcoholic liver disease. J Pathol 2003; 201: 5562.
  • 19
    Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38: 257265.
  • 20
    Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002; 1: 3.
  • 21
    Imbert-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004; 42: 323333.
  • 22
    Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of hepatitis C patients without hepatic fibrosis by a simple predictive model. HEPATOLOGY 2002; 36: 986992.
  • 23
    Wai CT, Greenson JK, Fontana RJ, Kalbfleish JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 518526.
  • 24
    Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and Fibrotest. HEPATOLOGY 2007; 46: 3236.
  • 25
    Pugh R, Murray-Lyon I, Dawson J, Pietroni M, Williams R. Transection of the oesophagus for bleeding oesophagus varices. Br J Surg 1973; 60: 646649.
  • 26
    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non parametric approach. Biometrics 1988; 44: 837845.
  • 27
    Zhou X, Obuchowski N, McClish D. Statistical methods in diagnostic medicine. New York: John Wiley & Sons; 2002.
  • 28
    Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007; 53: 16151622.
  • 29
    Poynard T, Halfon P, Castera L, Charlotte F, Bail BL, Munteanu M, et al. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 2007; 25: 733739.
  • 30
    Vallin J, Meslé F. Tables de mortalité françaises pour les XIXe et XXe siècles et projections pour le XXIe siècle. Paris, France: Institut National d'Etudes Démographiques; 2001.
  • 31
    Ederer F, Heise H. Instructions to IBM 650 Programmers in Processing Survival Computations. Methodological Note No. 10, End Results Evaluation Section. Bethesda, MD: National Cancer Institute; 1959.
  • 32
    Hintze JL. NCSS 2007 User Guide. Number Cruncher Statisticak Systems 2007 software. Kaysville, UT: NCSS; 2007.
  • 33
    Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 395402.
  • 34
    Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 775782.
  • 35
    Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996; 110: 18471853.
  • 36
    Thabut D, Simon M, Myers RP, Messous D, Thibaut V, Imbert-Bismut F, et al. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. HEPATOLOGY 2003; 37: 12201221.
  • 37
    Morra R, Lebray P, Ingiliz P, Ngo Y, Munteanu M, Ratziu V, et al. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. HEPATOLOGY 2008; 47: 353354.
  • 38
    Adler M, Gulbis B, Moreno C, Evrard S, Verset G, Golstein P, et al. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. HEPATOLOGY 2008; 47: 762763.
  • 39
    Poynard T, Zourabichvili O, Hilpert G, Naveau S, Poitrine A, Benatar C, et al. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. HEPATOLOGY 1984; 4: 324327.